Literature DB >> 23055271

Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.

Peter K Gregersen1, Roman Kosoy, Annette T Lee, Janine Lamb, Jon Sussman, David McKee, Kim R Simpfendorfer, Ritva Pirskanen-Matell, Frederik Piehl, Qiang Pan-Hammarstrom, Jan J G M Verschuuren, Maarten J Titulaer, Erik H Niks, Alexander Marx, Philipp Ströbel, Björn Tackenberg, Michael Pütz, Angelina Maniaol, Ahmed Elsais, Chantal Tallaksen, Hanne F Harbo, Benedicte A Lie, Soumya Raychaudhuri, Paul I W de Bakker, Arthur Melms, Henri-Jean Garchon, Nicholas Willcox, Lennart Hammarstrom, Michael F Seldin.   

Abstract

OBJECTIVE: The objective of this study is to comprehensively define the genetic basis of early onset myasthenia gravis (EOMG).
METHODS: We have carried out a 2-stage genome-wide association study on a total of 649 North European EOMG patients. Cases were matched 1:4 with controls of European ancestry. We performed imputation and conditional analyses across the major histocompatibility complex, as well as in the top regions of association outside the human leukocyte antigen (HLA) region.
RESULTS: We observed the strongest association in the HLA class I region at rs7750641 (p = 1.2 × 10(-92) ; odds ratio [OR], 6.25). By imputation and conditional analyses, HLA-B*08 proves to be the major associated allele (p = 2.87 × 10(-113) ; OR, 6.41). In addition to the expected association with PTPN22 (rs2476601; OR, 1.71; p = 8.2 × 10(-10) ), an imputed coding variant (rs2233290) at position 151 (Pro→Ala) in the TNFAIP3-interacting protein 1, TNIP1, confers even stronger risk than PTPN22 (OR, 1.91; p = 3.2 × 10(-10) ).
INTERPRETATION: The association at TNIP1 in EOMG implies disease mechanisms involving ubiquitin-dependent dysregulation of NF-κB signaling. The localization of the major HLA signal to the HLA-B*08 allele suggests that CD8(+) T cells may play a key role in disease initiation or pathogenesis.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055271      PMCID: PMC3535539          DOI: 10.1002/ana.23691

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

1.  A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C.

Authors:  M Janer; A Cowland; J Picard; D Campbell; P Pontarotti; J Newsom-Davis; M Bunce; K Welsh; A Demaine; A G Wilson; N Willcox
Journal:  Hum Immunol       Date:  1999-09       Impact factor: 2.850

2.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

3.  Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.

Authors:  Daniel Falush; Matthew Stephens; Jonathan K Pritchard
Journal:  Genetics       Date:  2003-08       Impact factor: 4.562

Review 4.  Genomics and the multifactorial nature of human autoimmune disease.

Authors:  Judy H Cho; Peter K Gregersen
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

Review 5.  Recent advances in the genetics of systemic lupus erythematosus.

Authors:  Donna L Thibault Flesher; Xin Sun; Timothy W Behrens; Robert R Graham; Lindsey A Criswell
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

6.  Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors:  Patrice Nancy; Sonia Berrih-Aknin
Journal:  Endocrinology       Date:  2005-01-20       Impact factor: 4.736

Review 7.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 9.  ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.

Authors:  Lynn Verstrepen; Isabelle Carpentier; Kelly Verhelst; Rudi Beyaert
Journal:  Biochem Pharmacol       Date:  2009-02-27       Impact factor: 5.858

10.  LYP inhibits T-cell activation when dissociated from CSK.

Authors:  Torkel Vang; Wallace H Liu; Laurence Delacroix; Shuangding Wu; Stefan Vasile; Russell Dahl; Li Yang; Lucia Musumeci; Dana Francis; Johannes Landskron; Kjetil Tasken; Michel L Tremblay; Benedicte A Lie; Rebecca Page; Tomas Mustelin; Souad Rahmouni; Robert C Rickert; Lutz Tautz
Journal:  Nat Chem Biol       Date:  2012-03-18       Impact factor: 15.040

View more
  54 in total

Review 1.  [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].

Authors:  C-A Weis; B Märkl; T Schuster; K Vollert; P Ströbel; A Marx
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 2.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

3.  HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Authors:  E K K Henriksen; M K Viken; M Wittig; K Holm; T Folseraas; S Mucha; E Melum; J R Hov; K N Lazaridis; B D Juran; O Chazouillères; M Färkkilä; D N Gotthardt; P Invernizzi; M Carbone; G M Hirschfield; S M Rushbrook; E Goode; C Y Ponsioen; R K Weersma; B Eksteen; K K Yimam; S C Gordon; D Goldberg; L Yu; C L Bowlus; A Franke; B A Lie; T H Karlsen
Journal:  HLA       Date:  2017-07-11       Impact factor: 4.513

Review 4.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

5.  Increased risk for clinical onset of myasthenia gravis during the postpartum period.

Authors:  Marion I Boldingh; Angelina H Maniaol; Cathrine Brunborg; Harald Weedon-Fekjær; Jan J G M Verschuuren; Chantal M E Tallaksen
Journal:  Neurology       Date:  2016-10-21       Impact factor: 9.910

6.  Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.

Authors:  Adam P Levine; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Edwin K S Wong; H Terence Cook; Sofie Ashford; Keren Carss; Martin T Christian; Matthew Hall; Claire Louise Harris; Paul McAlinden; Kevin J Marchbank; Stephen D Marks; Heather Maxwell; Karyn Megy; Christopher J Penkett; Monika Mozere; Kathleen E Stirrups; Salih Tuna; Julie Wessels; Deborah Whitehorn; Sally A Johnson; Daniel P Gale
Journal:  J Am Soc Nephrol       Date:  2020-01-09       Impact factor: 10.121

7.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

8.  Gene Polymorphisms for Both Auto-antigen and Immune-Modulating Proteins Are Associated with the Susceptibility of Autoimmune Myasthenia Gravis.

Authors:  Hai-Feng Li; Yu Hong; Xu Zhang; Yanchen Xie; Geir Olve Skeie; Hong-Jun Hao; Nils Erik Gilhus; Bing Liang; Yao-Xian Yue; Xian-Jun Zhang; Xiang Gao; Qi Wang; Zhe Gao; Xiao-Jun Ding; Min Song
Journal:  Mol Neurobiol       Date:  2016-08-08       Impact factor: 5.590

Review 9.  The immunogenetics of neurological disease.

Authors:  Maneesh K Misra; Vincent Damotte; Jill A Hollenbach
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

Review 10.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.